{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:18:07Z","timestamp":1787807887035,"version":"build-2784847793"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A) is an inflammatory disorder of the central nervous system. The clinical implications of Epstein\u2013Barr virus (EBV) sequences detected in cerebrospinal fluid (CSF) by metagenomic next-generation sequencing (mNGS) remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter retrospective cohort study enrolled 60 patients with GFAP-A screened from electronic medical records of two hospitals (Jan 2019\u2013Dec 2025). Patients were stratified into CSF EBV-positive (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f10) and CSF EBV-negative (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f50) groups based on CSF mNGS results. Demographic characteristics, clinical manifestations, laboratory findings, MRI features, treatment, and outcomes were compared. Bonferroni correction was applied to three clinically prioritized endpoints (CSF white blood cell count, altered consciousness, CSF chloride) selected based on prior GFAP-A literature to limit multiplicity bias; the corrected two-sided significance threshold was set at\n                      <jats:italic>\u03b1<\/jats:italic>\n                      \u202f=\u202f0.05\/3\u202f\u2248\u202f0.0167. An exploratory Firth penalized multivariable logistic regression model fitted via R (v4.3.1, logistf package) was used to examine the adjusted associations between CSF mNGS-detectable EBV sequences and acute altered consciousness, adjusting for age and sex to mitigate small-sample bias. All other unadjusted baseline comparisons were considered exploratory and were not adjusted for multiplicity. Spearman\u2019s rank correlation was used to assess the relationships of raw EBV mNGS read counts with peak pretreatment modified Rankin Scale (mRS) score and CSF WBC count among EBV-positive patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CSF WBC count was higher in the CSF EBV-positive group than in the CSF EBV-negative group [median, 120 (interquartile range, 105\u2013220) vs. 33 (16\u201397)\u202f\u00d7\u202f10\u2076\/L; raw\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004; Bonferroni-adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.012]. Altered consciousness was more frequent in the EBV-positive group (80.0% vs. 42.0%; crude odds ratio [OR]\u202f=\u202f5.52, 95% confidence interval [CI] 1.06\u201328.71; raw\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.039), and CSF chloride was numerically lower [111.50 (104.00\u2013117.00) vs. 115.70 (113.00\u2013120.00) mmol\/L; raw\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.048]; however, neither comparison met the Bonferroni-corrected criterion (adjusted\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.117 and 0.144, respectively). Firth penalized multivariable logistic regression fitted in R was adjusted for age and sex. CSF EBV positivity exhibited a non-significant trend toward higher odds of acute altered consciousness (OR\u202f=\u202f4.10, 95% CI: 0.94\u201324.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.060). The extremely wide confidence interval indicated high estimation uncertainty limited by the small EBV-positive subgroup (n\u202f=\u202f10). Female sex was associated with lower estimated odds of altered consciousness (OR\u202f=\u202f0.17, 95% CI: 0.04\u20130.58,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.004), while age showed no independent association (OR\u202f=\u202f0.98, 95% CI: 0.95\u20131.02,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.312). No statistically detectable between-group differences were observed in GFAP-IgG characteristics, MRI findings, relapse, or functional outcomes. Among the 10 EBV-positive patients, raw EBV read counts were not statistically correlated with peak pretreatment mRS score (\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>s<\/jats:sub>\n                      \u202f=\u202f0.118,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.745) or CSF WBC count (\n                      <jats:italic>r<\/jats:italic>\n                      <jats:sub>s<\/jats:sub>\n                      \u202f=\u202f\u22120.073,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.841).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CSF WBC count was the only clinically prioritized comparison that remained statistically significant after Bonferroni correction, suggesting greater CSF pleocytosis and possibly increased intrathecal inflammatory activity in GFAP-A patients with mNGS-detectable CSF EBV. Differences in altered consciousness and CSF chloride remained inconclusive after multiplicity adjustment. Within the EBV-positive subgroup, raw EBV sequencing reads showed no correlation with inflammatory or disability measures. Current findings do not establish CSF EBV positivity as an independent pathogenic or prognostic biomarker for GFAP-A, and the biological origin of the detected EBV sequences remains uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1906448","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:17Z","timestamp":1787804777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features associated with cerebrospinal fluid Epstein\u2013Barr virus positivity in autoimmune GFAP astrocytopathy: a multicenter retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xing","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Neurology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Quan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzi","family":"Zhangbao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Huashan Hospital Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Huashan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaneurol.2016.2549","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis","volume":"73","author":"Fang","year":"2016","journal-title":"JAMA Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"577718","DOI":"10.1016\/j.jneuroim.2021.577718","article-title":"Clinical, neuroradiological, diagnostic and prognostic profile of autoimmune glial fibrillary acidic protein astrocytopathy: a pooled analysis of 324 cases from published data and a single-center retrospective study","volume":"360","author":"Xiao","year":"2021","journal-title":"J Neuroimmunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.mayocp.2019.02.003","article-title":"Neurologic autoimmunity in the era of checkpoint inhibitor Cancer immunotherapy","volume":"94","author":"Zekeridou","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1258048","DOI":"10.3389\/fimmu.2023.1258048","article-title":"Autoimmune GFAP astrocytopathy after viral encephalitis: a case report of bimodal overlapping encephalitis","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s40001-024-01926-0","article-title":"The EBV connection: a severe case of GFAP-A with central hypoventilation unresponsive to IVIG and literature review","volume":"29","author":"Wang","year":"2024","journal-title":"Eur J Med Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1111\/cns.14336","article-title":"Epstein-Barr virus: To be a trigger of autoimmune glial fibrillary acidic protein astrocytopathy?","volume":"29","author":"Li","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e31995","DOI":"10.1097\/MD.0000000000031995","article-title":"A case of EBV encephalomyelitis with positive anti-GFAP-IgG antibody with recurrent fever and dysuresia as the main symptoms: case report and retrospective analysis","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"578174","DOI":"10.1016\/j.jneuroim.2023.578174","article-title":"Overlapping Epstein-Barr virus encephalitis and autoimmune glial fibrillary acidic protein astrocytopathy","volume":"382","author":"Zhang","year":"2023","journal-title":"J Neuroimmunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jneuroim.2018.04.016","article-title":"Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1\u202fyear","volume":"321","author":"Dubey","year":"2018","journal-title":"J Neuroimmunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.2169\/internalmedicine.4741-24","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy caused by influenza A infection","volume":"64","author":"Okano","year":"2025","journal-title":"Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2169\/internalmedicine.2751-23","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy following SARS-CoV-2 infection","volume":"63","author":"Tajiri","year":"2024","journal-title":"Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1212\/CPJ.0000000000000790","article-title":"Dengue-associated postinfectious meningoencephalomyelitis with positive anti-GFAP antibody","volume":"11","author":"Martin","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr virus and systemic autoimmune diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ddmod.2020.01.001","article-title":"Epstein-Barr virus infection in the development of neurological disorders","volume":"32","author":"Soldan","year":"2020","journal-title":"Drug Discov Today Dis Model"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jnnp-2025-336773","article-title":"Intrathecal Epstein-Barr virus reactivation in patients with autoimmune glial fibrillary acidic protein astrocytopathy","volume":"97","author":"Handa","year":"2026","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s13760-023-02268-0","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: clinical analysis and review of 15 cases","volume":"123","author":"Lan","year":"2023","journal-title":"Acta Neurol Belg"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1375971","DOI":"10.3389\/fneur.2024.1375971","article-title":"Clinical characteristics and MRI features of autoimmune glial fibrillary acidic protein astrocytopathy: a case series of 34 patients","volume":"15","author":"Ke","year":"2024","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.DMIH2-0011-2015","article-title":"Epstein-Barr virus","volume":"4","author":"Nowalk","year":"2016","journal-title":"Microbiol Spectrum"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.42.33","article-title":"Epstein-Barr virus infections of the central nervous system","volume":"42","author":"Fujimoto","year":"2003","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7722","DOI":"10.1128\/JVI.73.9.7722-7733.1999","article-title":"Epstein-Barr virus infection of human astrocyte cell lines","volume":"73","author":"Menet","year":"1999","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.virol.2021.04.005","article-title":"Glial cell response to Epstein-Barr virus infection: a plausible contribution to virus-associated inflammatory reactions in the brain","volume":"559","author":"Jakhmola","year":"2021","journal-title":"Virology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/jnnp-2022-330626","article-title":"Early autoimmunity and outcome in virus encephalitis: a retrospective study based on tissue-based assay","volume":"94","author":"Liu","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1906448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:26:18Z","timestamp":1787804778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1906448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":24,"alternative-id":["10.3389\/fneur.2026.1906448"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1906448","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"article-number":"1906448"}}